Appendix A2: Description of the 22 of STROBE Statement—checklist of items that should be included in reports of observational studies

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Item**  **No** |  |  |
| **Title and abstract** | 1 | (*a*) Indicate the study’s design with **Title and abstract** 1 a commonly used term in the title or the abstract | ✓ |
|  |  | (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found |  |
| **Introduction** |  |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | ✓ |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | ✓ |
| **Methods** |  |  |  |
| Study design | 4 | Present key elements of study design early in the paper | ✓ |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment,  exposure, follow-up, and data collection | ✓ |
| Participants | 6 | (*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of  selection of participants. Describe methods of follow-up  *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants | ✓ |
|  |  | (*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed  *Case-control study*—For matched studies, give matching criteria and the number of  controls per case |  |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | ✓ |
| Data sources/  measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | ✓ |
| Bias | 9 | Describe any efforts to address potential sources of bias | 🗶 |
| Study size | 10 | Explain how the study size was arrived at | 🗶 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable,  describe which groupings were chosen and why | ✓ |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | ✓ |
|  |  | (*b*) Describe any methods used to examine subgroups and interactions |  |
|  |  | (*c*) Explain how missing data were addressed |  |
|  |  | (*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed  *Case-control study*—If applicable, explain how matching of cases and controls was addressed  *Cross-sectional study*—If applicable, describe analytical methods taking account of  sampling strategy |  |
|  |  | (*e*) Describe any sensitivity analyses |  |
| **Results** |  |  |  |
| Participants | 13 | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | ✓ |
|  |  | (b) Give reasons for non-participation at each stage |  |
|  |  | (c) Consider use of a flow diagram |  |
| Descriptive  data | 14 | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | ✓ |
|  |  | (b) Indicate number of participants with missing data for each variable of interest |  |
|  |  | (c) *Cohort study*—Summarise follow-up time (eg, average and total amount) |  |
| Outcome data | 15 | *Cohort study*—Report numbers of outcome events or summary measures over time | ✓ |
|  |  | *Case-control study—*Report numbers in each exposure category, or summary measures of  exposure |  |
|  |  | *Cross-sectional study—*Report numbers of outcome events or summary measures |  |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and  why they were included | ✓ |
|  |  | (*b*) Report category boundaries when continuous variables were categorized |  |
|  |  | (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful  time period |  |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | ✓ |
| **Discussion** |  |  |  |
| Key results | 18 | Summarise key results with reference to study objectives | ✓ |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision.  Discuss both direction and magnitude of any potential bias | ✓ |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity  of analyses, results from similar studies, and other relevant evidence | ✓ |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | ✓ |
| **Other information** |  |  |  |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable,  for the original study on which the present article is based | ✓ |